Development of novel DNA vaccine for VEGF in murine cancer model

Mariko Kyutoku, Hironori Nakagami, Hiroshi Koriyama, Hideki Tomioka, Futoshi Nakagami, Munehisa Shimamura, Hitomi Kurinami, Pang Zhengda, Dong Hyun Jo, Jeong Hun Kim, Nobuyuki Takakura, Ryuichi Morishita

Research output: Contribution to journalArticle

14 Scopus citations


We developed DNA vaccine for vascular endothelial growth factor (VEGF), which may provide the therapeutic option instead of anti-VEGF antibody, bevacizumab. Plasmid containing VEGF mini-gene was constructed in the insertion of B-cell epitope of Hepatitis B core protein [HBc-VEGF], which was an epitope carrier. High titer of anti-VEGF antibody was observed in BALB/c mice which were intramuscularly immunized with HBc-VEGF by electropolator. In mice inoculated with colon 26 cells, tumor volume and microvessel density was decreased in HBc-VEGF with a significant prolonged survival. Co-treatment of purified IgG from immunized mice with HBc-VEGF showed in vitro neutralizing activity for VEGF-induced ERK phosphorylation and tube formation in cultured endothelial cells. Furthermore, intravitreally injection of this purified IgG reduced the neovessel formation in the mouse oxygen-induced retinopathy and laser-induced choroidal neovascularization models. These results first provided that DNA vaccine against VEGF possessed the anti-angiogenic effect, leading to prolonged survival in mouse cancer model.

Original languageEnglish
Article number3380
JournalScientific Reports
StatePublished - 29 Nov 2013

Cite this

Kyutoku, M., Nakagami, H., Koriyama, H., Tomioka, H., Nakagami, F., Shimamura, M., Kurinami, H., Zhengda, P., Jo, D. H., Kim, J. H., Takakura, N., & Morishita, R. (2013). Development of novel DNA vaccine for VEGF in murine cancer model. Scientific Reports, 3, [3380].